| Duvie (lobeglitazone) / Chong Kun Dang |
NCT02315287: Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management |
|
|
| Recruiting | 4 | 190 | RoW | Pioglitazone, Actos, Lobeglitazone, Duvie | Seoul National University Bundang Hospital | Type 2 Diabetes | 12/21 | 12/21 | | |
| Recruiting | 4 | 99 | RoW | Dapagliflozin 10mg Tab, Forxiga 10mg, Lobeglitazone 0.5 mg, Duvie 0.5 mg, Dapagliflozin + Lobeglitazone, Forxiga 10mg + Duvie 0.5mg | Seoul National University Bundang Hospital | Diabetes Type 2 | 10/23 | 12/23 | | |
NCT03641352: The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes |
|
|
| Recruiting | 3 | 240 | RoW | CKD-501 0.5mg, Lobeglitazone, Placebo | Chong Kun Dang Pharmaceutical | Type2 Diabetes | 04/21 | 11/22 | | |
NCT03627182: Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes |
|
|
| Recruiting | 3 | 240 | RoW | CKD-501 0.5mg, Lobeglitazone 0.5mg, Placebo | Chong Kun Dang Pharmaceutical | Type2 Diabetes | 03/22 | 02/23 | | |
NCT04706286: Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393 |
|
|
| Not yet recruiting | 1 | 26 | RoW | CKD-501, D759, D150, Treatment A, CKD-393 0.5/100/1000 mg, Treatment B | Chong Kun Dang Pharmaceutical | T2DM (Type 2 Diabetes Mellitus) | 03/21 | 04/21 | | |
NCT05113693: Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393 |
|
|
| Completed | 1 | 33 | RoW | CKD-393, CKD-501, D759, H053 | Chong Kun Dang Pharmaceutical | Type 2 Diabetes | 12/21 | 12/21 | | |
NCT05816759: Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150 |
|
|
| Completed | 1 | 32 | RoW | CKD-383, CKD-501, D744, D150 | Chong Kun Dang Pharmaceutical | Type 2 Diabetes | 06/23 | 06/23 | | |
NCT05897216: Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029 |
|
|
| Completed | 1 | 30 | RoW | CKD-383, CKD-501, D745, D150, D029 | Chong Kun Dang Pharmaceutical | Type 2 Diabetes | 07/23 | 08/23 | | |
NCT06483243: Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State. |
|
|
| Completed | 1 | 45 | RoW | Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG, Test: CKD-383, Reference1: CKD-501, Reference2: D745, Reference3: D150 | Chong Kun Dang Pharmaceutical | Type 2 Diabetes Mellitus | 04/24 | 05/24 | | |
NCT06492655: To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers |
|
|
| Not yet recruiting | 1 | 28 | NA | CKD-383(Fed), Lobeglitazone, Empagliflozin, Metformin, CKD-383(Fasted) | Chong Kun Dang Pharmaceutical | Type 2 Diabetes Mellitus | 08/24 | 08/24 | | |
